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Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
Trials 2019, 20(Suppl 1):P-2
Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.
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The UK plasma based Molecular profiling of Advanced breast cancer
to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple
parallel-cohort, phase IIa platform trial aiming to provide proof of
principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
Sarah Kernaghan1, Laura Moretti1, Lucy Kilburn1, Katie Wilkinson1, Claire
Snowdon1, James Morden1, Iain Macpherson2, Andrew Wardley3,
Rebecca Roylance4, Richard Baird5, Alistair Ring6, Nicholas Turner7,
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Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was added
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Professions Research Unit), University of Stirling & Medical Research
Council (MRC) ConDuCT II Hub for Trials Methodology Research, United
Kingdom
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Introduction : A standalone external pilot explores the feasibility of
performing a definitive RCT, with outcome data not routinely com-
bined with data from the subsequent RCT. An internal pilot is de-
signed and conducted as the first phase of an RCT, with outcome
data included in the main analysis. When to perform an internal or
external pilot is poorly understood. Qualitative work is needed to ex-
plore the views and perceptions of funders regarding how, when
and why to choose an external or internal pilot study design.
Methods: Purposive sampling identified participants from UK funding
panels including NIHR (HTA/RfPB/EME/PGfAR) CRUK, CSO and ARUK.
Maximum variation sampling ensured inclusion of multiple character-
istics, including chair/deputy chair/member positions on different
funding panels and various methodological roles. Semi-structured in-
terviews performed face-to-face or by telephone using a topic guide
explored participants’ views and practices of funding pilot work. Data
analyses were conducted according to principles of thematic analysis,
in an iterative and cyclical process as further interviews were con-
ducted and until no new themes emerged or evolved.
Results: Of 27 participants contacted, 19(70%) consented and were
interviewed in three iterative phases (mean duration 59minutes, range
30-88). Most participants agreed an external pilot design should be
chosen when substantial uncertainty exists about one or more design
parameters. Of these parameters, a stable, deliverable and acceptable
intervention was perceived by most as essential for proceeding to a
main trial. Some discussed how staged funding for external pilot stud-
ies progressing to a feasible main trial could improve efficiency and
limit waste, through avoiding conduct of studies with little hope of
main trial funding. Others felt an open ended funding strategy pre-
sented significant logistical difficulties, despite it’s appeal.
Conclusion: Future work will focus on developing recommendations
for when to do an external pilot, and establishing whether a flexible
design model is possible.
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- O2 Exploring patient treatment preferences enhances trial
recruitment, so why do trial recruiters often avoid doing it?
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Introduction: Patient treatment preferences are one of the most
common preventable reasons for poor trial recruitment. Exploring
treatment preferences during trial consultations entails eliciting and
acknowledging the reasons for a patient’s preference and providing
information to balance treatment views. Doing so can improve in-
formed consent, trial recruitment and retention. We examined how
trial recruiters respond to treatment preferences during consultations
and recruiters’ views about exploring treatment preferences.
Methods: Transcribed audio-recordings of 128 trial consultations from
97 patients and semi-structured interviews with 53 trial recruiters (sur-
geons, oncologists, and nurses) from two multicentre trials (CONTRACT
ISRCTN15830435; ROAM/EORTC-1308 ISRCTN71502099). Data analysis
was thematic.
Results: Initially, few recruiters elicited treatment preferences but fol-
lowing training they increasingly did so. However, contrary to the train-
ing, recruiters’ exploration and balancing of preferences tended to be
asymmetrical - they particularly avoided exploring and balancing pref-
erences when the patient’s preference aligned with the recruiter’s own
preference. In one of the trials, this often resulted in the patient declin-
ing to participate. Recruiters spoke of being reluctant to explore and
balance preferences and some attributed this to concerns about unduly
influencing patients to participate. Some thought preference explor-
ation would take too much time or would conflict with their clinical re-
sponsibilities to advise patients about treatments.
Discussion: Despite trial communication training, recruiters were
hesitant to explore patient treatment preferences. Consequently,
patients will often be relying on suboptimal information about
treatments to inform their decisions about trials. Emphasising that
preference exploration, regardless of the recruiter’s own prefer-
ence, is consistent with a supported and informed approach to
decision-making could help to overcome recruiters’ concerns. Evi-
dence on the perspectives of patients on treatment preference
exploration would inform recruiter training and practice. Trialists
also need to consider the potential impact of recruiter biases on
trial communication when designing future trials that compare
markedly different treatments.
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Introduction: Trials within Cohorts (TwiCs) is an innovative approach
to the design and conduct of multiple randomised controlled trials
(RCTs) (Relton et al, 2010). This approach utilises an observational co-
hort to recruit trial populations and obtain short and longer term
outcomes. We describe what is currently known about the use of this
design approach.
Methods: An extension of the 2010 Consolidated Standards of
Reporting Trials (CONSORT) Statements for RCTs using cohorts and/
or routinely collected health data is in development, supported by a
scoping review that includes publications of methods or reports of
protocols or results from RCTs using cohorts, registries, electronic
health records and administrative databases. Data sources for this
scoping review included Medline and Cochrane Methodology Regis-
ter and were limited to English language.
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